158 related articles for article (PubMed ID: 28870123)
21. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
[TBL] [Abstract][Full Text] [Related]
22. Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials.
Durkan AM; Hodson EM; Willis NS; Craig JC
Kidney Int; 2001 May; 59(5):1919-27. PubMed ID: 11318964
[TBL] [Abstract][Full Text] [Related]
23. Which children with nephrotic syndrome benefit from cyclosporin A or cyclophosphamide?
Coulthard MG
Pediatr Nephrol; 2009 Jun; 24(6):1257; author reply 1259. PubMed ID: 19189132
[No Abstract] [Full Text] [Related]
24. Evaluation and management of steroid-sensitive nephrotic syndrome.
Hodson EM; Alexander SI
Curr Opin Pediatr; 2008 Apr; 20(2):145-50. PubMed ID: 18332709
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome.
de Mello VR; Rodrigues MT; Mastrocinque TH; Martins SP; de Andrade OV; Guidoni EB; Scheffer DK; Martini Filho D; Toporovski J; Benini V
Pediatr Nephrol; 2010 Mar; 25(3):453-60. PubMed ID: 19937060
[TBL] [Abstract][Full Text] [Related]
26. Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.
Tellier S; Dallocchio A; Guigonis V; Saint-Marcoux F; Llanas B; Ichay L; Bandin F; Godron A; Morin D; Brochard K; Gandia P; Bouchet S; Marquet P; Decramer S; Harambat J
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1777-1782. PubMed ID: 27445161
[TBL] [Abstract][Full Text] [Related]
27. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
Berchialla P; Zohar S; Baldi I
Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
[TBL] [Abstract][Full Text] [Related]
28. [Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children].
Ogarek I; Szczęsny-Choruz E; Wierzchowska-Słowiaczek E; Kwinta-Rybicka J; Stec Z; Moczulska A; Wilkosz K; Drożdż D
Pol Merkur Lekarski; 2018 Apr; 44(262):192-195. PubMed ID: 29775447
[TBL] [Abstract][Full Text] [Related]
29. Robust meta-analytic-predictive priors in clinical trials with historical control information.
Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
[TBL] [Abstract][Full Text] [Related]
30. Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: Application to the IMPROVE trial.
Mason AJ; Gomes M; Grieve R; Ulug P; Powell JT; Carpenter J
Clin Trials; 2017 Aug; 14(4):357-367. PubMed ID: 28675302
[TBL] [Abstract][Full Text] [Related]
31. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
Moatti M; Chevret S; Zohar S; Rosenberger WF
Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
[TBL] [Abstract][Full Text] [Related]
32. Bayesian sample size determination using commensurate priors to leverage preexperimental data.
Zheng H; Jaki T; Wason JMS
Biometrics; 2023 Jun; 79(2):669-683. PubMed ID: 35253201
[TBL] [Abstract][Full Text] [Related]
33. Clinical Trials in FSGS: Past Challenges and New Trial Designs.
Gipson D
Semin Nephrol; 2016 Nov; 36(6):453-459. PubMed ID: 27987544
[No Abstract] [Full Text] [Related]
34. Constructing Relative Effect Priors for Research Prioritization and Trial Design: A Meta-epidemiological Analysis.
Glynn D; Nikolaidis G; Jankovic D; Welton NJ
Med Decis Making; 2023 Jul; 43(5):553-563. PubMed ID: 37057388
[TBL] [Abstract][Full Text] [Related]
35. Should we consider MMF therapy after rituximab for nephrotic syndrome?
Filler G; Huang SH; Sharma AP
Pediatr Nephrol; 2011 Oct; 26(10):1759-62. PubMed ID: 21533869
[TBL] [Abstract][Full Text] [Related]
36. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
37. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.
Gulati A; Sinha A; Gupta A; Kanitkar M; Sreenivas V; Sharma J; Mantan M; Agarwal I; Dinda AK; Hari P; Bagga A
Kidney Int; 2012 Nov; 82(10):1130-5. PubMed ID: 22763815
[TBL] [Abstract][Full Text] [Related]
38. Evaluation and management of steroid-unresponsive nephrotic syndrome.
Del Rio M; Kaskel F
Curr Opin Pediatr; 2008 Apr; 20(2):151-6. PubMed ID: 18332710
[TBL] [Abstract][Full Text] [Related]
39. New treatment strategies in idiopathic nephrotic syndrome.
Ulinski T; Aoun B
Minerva Pediatr; 2012 Apr; 64(2):135-43. PubMed ID: 22495188
[TBL] [Abstract][Full Text] [Related]
40. Therapies for steroid-resistant nephrotic syndrome.
Hodson EM; Craig JC
Pediatr Nephrol; 2008 Sep; 23(9):1391-4. PubMed ID: 18368428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
